account_balance
Investment manager · 13F filer · SEC CIK 1839948
TCG Crossover Management, LLC
Reported value$4.16Bas of Jun 30, 2026
Positions54 12 new, 7 sold out
Top 10 weight57%ABVX alone is 19%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
ABVX
Abivax SA American Depositary Shares
19.2%Trimmed
TNGX
Tango Therapeutics INC
6.8%Trimmed
CGON
Cg Oncology INC
6.3%
COGT
Cogent Biosciences INC
4.5%
IMVT
Immunovant INC
4.1%
SYRE
Spyre Therapeutics INC
4.1%
DNTH
Dianthus Therapeutics INC
3.9%
MIRM
Mirum Pharmaceuticals INC
3.0%
ZLAB
Zai Lab Ltd-adr
2.8%New
AMLX
Amylyx Pharmaceuticals INC
2.7%
44 others
42.6%
Box size is the share of the fund's reported holdings. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
What changed